Pharmacogenomics of Heparin-Induced Thrombocytopenia
ConditionHeparin-induced Thrombocytopenia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Arizona
About this trial
The purpose of this research is to identify genomic markers that can predict heparin-induced thrombocytopenia (HIT), which is a very serious side effect to heparin. Heparin is commonly used to prevent blood clots and the investigators may be able to identify genomic markers which can be used to prevent heparin use in people who will get HIT.
Eligibility criteria
Qualifiers
18 years of age or older
Ability to give informed consent
Have undergone testing for heparin/PF4 antibody with or without SRA testing for HIT
Have received treatment with unfractionated heparin or low molecular weight heparin (enoxaparin, dalteparin, tinzaparin) prior to antibody or SRA testing
Disqualifiers
Less than 18 years of age
Pregnancy
Hemoglobin less than 9 mg/dL (for larger 5 ounce blood draw)
Known Human Immunodeficiency Virus (HIV) infection
Trial design
Treatments tested in this trial
- Blood Draw
Treatment groups
125 Participants
are divided into 1 treatment groupSponsors and collaborators
University of Arizona
Lead sponsor
American College of Clinical Pharmacy
Collaborator
Source ClinicalTrials.gov